What Aqsitania does

Aqsitania SAS is a privately held French deep-tech company, founded in February 2014 and headquartered in Pessac near Bordeaux, that develops a proprietary signal-processing technology called AMASR (Analyse Morphologique Anharmonique des Signaux Respiratoires) for respiratory function assessment. The technology, originated by co-founder and President Patrick Hanusse after long theoretical research, is positioned as a break from conventional Fourier and wavelet approaches, enabling the extraction of fine-grained information from periodic respiratory waveforms to generate a unique Personal Respiratory Profile (PRP) for each patient. Its flagship product, Ventilom\u00e9trie, is a gentle, effort-free respiratory test applicable to all patient populations (children through elderly) that feeds the PRP and supports early detection of adverse events such as exacerbations, respiratory failure, and pulmonary edema.

The company commercializes this technology through three product lines: (1) T\u00e9l\u00e9surveillance, a home-based remote-monitoring service for chronic respiratory patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants); (2) Ventilosmart, a consumer mobile application extending the technology to professional athletes and the general public for respiratory self-evaluation; and (3) bespoke AMAS signal-analysis services for adjacent physiological signals (cardiac, cardio-respiratory, sleep) for industrial and academic clients. Revenue is generated through recurring telemonitoring engagements with French university hospitals (CHU) and pharmaceutical partner Chiesi (via the WeStart program co-run with IBM), supplemented by professional-services revenue from custom projects.

Aqsitania's commercial footprint remains small (1-10 employees, no disclosed VC funding, primary market France with nascent Spanish presence), and customer engagement is dominated by long-standing clinical research collaborations with major French university hospitals including AP-HP Piti\u00e9-Salp\u00e4tri\u00e8re, CHU de Bordeaux, Grenoble, Lyon, and Rouen, alongside academic partnerships with Universit\u00e9 Paris-Sorbonne, Bordeaux, and Grenoble-Alpes. Go-to-market relies on peer-reviewed clinical validation presented at the European Respiratory Society congresses, healthcare trade shows (HIT Paris, MWC/4YFN Barcelona, ConHIT Berlin), and a network of 2023 ecosystem memberships (FrenchTech, Les DeepTech, Barcelona Health Hub, Allis-NA). The company was recognized with the Concours national d'aide \u00e0 la cr\u00e9ation d'entreprises innovantes and the Troph\u00e9e de la e-sant\u00e9 awards.

Name

Aqsitania

Legal name

Aqsitania SAS

Website

https://aqsitania.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Aqsitania is a French deep-tech company that commercializes its proprietary AMASR respiratory signal-processing technology through Ventilom\u00e9trie telemonitoring for chronic respiratory patients, the Ventilosmart consumer app, and bespoke signal-analysis services for hospital, pharmaceutical, and sports clients.

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring

NAICS

Medical and Diagnostic Laboratories (62151), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Scientific and Technical Consulting Services (54169)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)

akta.pro secondary industries

Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI), General Pulmonology Practice (HLAKANAA), Allergy & Immunology Telemedicine Platforms (HLALAGAK)

Keywords

• Respiratory telemonitoring
• Signal analysis
• Ventilometry
• Chronic disease monitoring
• Respiratory diagnostics

Headquarters

HQ city

Pessac

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Telemonitoring/Telesurveillance Services: Recurring telemonitoring services for chronic respiratory patients enabling remote health monitoring from home, potentially subscription or service-based model.
2. Custom Signal Analysis Projects: Bespoke signal analysis project services for healthcare and other sectors using their proprietary AMAS technology, including cardiac, cardio-respiratory, and sleep signals.
3. Sports Respiratory Evaluation: Individual respiratory evaluation services for athletes and sports professionals, including personal respiratory profile establishment and long-term monitoring.
4. Signal Analysis Service: Analysis services helping clients improve time and quality of results in signal analysis studies using their unique AMAS technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Aqsitania provides respiratory telemonitoring and diagnostics for chronically ill patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) and professional athletes, powered by its proprietary AMASR signal processing technology. The company's core products include Ventilométrie (effort-free respiratory function assessment), the Personal Respiratory Profile (PRP), home-based telemonitoring services, the Ventilosmart consumer mobile application, and bespoke signal analysis projects. The technology enables new biomarkers and early detection of respiratory deterioration that traditional signal processing methods cannot identify.

Product overview

Aqsitania offers a unified product portfolio centered on its proprietary AMASR (Analyse Morphologique Anharmonique des Signaux Respiratoires) signal analysis technology. The core offering is Ventilométrie, a gentle respiratory function evaluation method that generates each patient's unique Personal Respiratory Profile (PRP). This feeds into two main service lines: (1) Télésurveillance — remote monitoring of chronic respiratory patients (asthma, COPD, cystic fibrosis, lung transplants) from home; and (2) Sport et auto-évaluation respiratoire — respiratory self-evaluation for athletes. The Ventilosmart sub-brand delivers the Ventilometry capability as a consumer-facing mobile application. Aqsitania also offers bespoke signal analysis and project management services for other physiological signal types (cardiac, sleep, etc.) using the same AMAS technology platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Ventilométrie (Ventilometry) Flagship diagnostic and monitoring method based on the AMASR technology. It enables fine-grained evaluation of respiratory function through the analysis of resting breathing patterns, requiring no patient effort and applicable to all patients from children to the elderly. Used for diagnosis, remote monitoring, and respiratory performance follow-up.
• Profil Respiratoire Personnel (PRP) - Personal Respiratory Profile A unique 'respiratory identity card' for each patient, defined through AMASR analysis during calm breathing. The PRP enables detection of deviations or anomalies in respiratory markers, allowing anticipation of adverse events (exacerbations, respiratory failure, pulmonary edema) and evaluation of treatment effects.
• Ventilosmart Individual consumer-facing mobile application version of Ventilometry, making respiratory function monitoring accessible to the general public and professional athletes in addition to hospital (CHU) usage.
• Télésurveillance des affections respiratoires chroniques (Chronic respiratory telemonitoring) Tele-monitoring service for chronic respiratory patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) enabling remote monitoring and patient safety at home using connected autonomous devices or mobile applications, aimed at reducing hospital readmissions.
• Sport et auto-évaluation respiratoire (Sports respiratory self-evaluation) Respiratory self-evaluation service for athletes based on simple measurements of normal breathing taken at rest or during an exercise protocol, enabling personalized respiratory monitoring, training personalization, and performance optimization.
• Analyse de Signaux (AMAS) - Custom signal analysis Custom signal analysis services for physiological signals (respiratory, cardiac, cardio-respiratory, sleep) using proprietary AMAS technology, offering clients a new vision of information carried by their signals with significantly improved analysis quality compared to traditional tools (Fourier, wavelets).
• Construction et Gestion de Projets (Project building and management) Collaborative project building and management service for custom signal analysis projects, implemented according to industry best practices within Aqsitania's scope of intervention.

Quantifiable outcome

• Clinical validation at major European respiratory congresses including ERS 2014 (Munich), ERS 2019 (Madrid), ERS 2022 (Barcelona) with peer-reviewed presentations

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Les DeepTechcoreGTM or Marketing Partner · 1 November 2023Aqsitania entered the 'Les DeepTech' community of disruptive startups in November 2023, recognizing its breakthrough technology and innovation in deep tech.
• Barcelona Health HubcoreGTM or Marketing Partner · 1 June 2023Aqsitania became a member of Barcelona Health Hub in June 2023, joining a digital health ecosystem focused on innovation in healthcare technology and international networking.
• FrenchTechcoreGTM or Marketing Partner · 1 March 2023Aqsitania became a member of the FrenchTech community in March 2023, gaining access to the French startup ecosystem support network and national visibility for innovative technology companies.
• WeStart (Chiesi and IBM)coreStrategic or Co-development Partner · 1 February 2020Aqsitania entered the WeStart program organized by pharmaceutical company Chiesi and technology company IBM, aimed at promoting and industrializing its innovation for chronic respiratory disease management. This strategic partnership provides access to pharmaceutical industry expertise and technological resources.
• AP-HP Hôpital de la Pitié-SalpêtrièrecoreStrategic or Co-development PartnerLong-standing clinical research partnership with Assistance Publique - Hôpitaux de Paris at La Pitié-Salpêtrière hospital for respiratory function characterization studies and clinical validation.
• CHU de BordeauxcoreStrategic or Co-development PartnerClinical collaboration with Centre Hospitalier Universitaire de Bordeaux for respiratory signal analysis research and clinical validation.
• CHU de GrenoblecoreStrategic or Co-development PartnerClinical research partnership with Centre Hospitalier Universitaire de Grenoble for respiratory function studies.
• CHU de LyoncoreStrategic or Co-development PartnerClinical collaboration with Centre Hospitalier Universitaire de Lyon for respiratory signal analysis research.
• CHU de RouencoreStrategic or Co-development PartnerHospital partnership with Centre Hospitalier Universitaire de Rouen for clinical research collaboration.
• Université Paris-SorbonnecoreStrategic or Co-development PartnerAcademic partnership with Sorbonne University for collaborative respiratory function research alongside APHP clinicians.
• Université de BordeauxcoreStrategic or Co-development PartnerAcademic collaboration with University of Bordeaux Hospital for clinical research in respiratory medicine.
• Université Grenoble-AlpescoreStrategic or Co-development PartnerAcademic partnership with Université Grenoble-Alpes (formerly Grenoble-Alphes) for respiratory research collaboration.
• Allis-NA Alliance Innovation SantéminorGTM or Marketing PartnerAlliance Innovation Santé member organization focused on health innovation in Nouvelle-Aquitaine region.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Direct peers

• TidalSense: TidalSense is a UK respiratory diagnostics and telehealth company using novel sensor and signal-analysis approaches (e.g., N-Tidal capnography) to diagnose and monitor chronic respiratory conditions — directly comparable in mission, technology approach, and clinical customer base to Aqsitania.
• NuvoAir: NuvoAir is a digital-health company offering remote respiratory monitoring, virtual pulmonary care, and connected spirometry for patients with asthma, COPD, and cystic fibrosis — directly mirroring Aqsitania's chronic-respiratory telemonitoring use cases and target customers (patients, providers, payers).
• Propeller Health (ResMed): Propeller Health (acquired by ResMed) provides connected inhaler sensors and digital respiratory health programs for asthma and COPD — a direct functional parallel to Aqsitania's Telesurveillance service for the same patient populations.
• Adherium: Adherium designs connected inhaler sensors and remote respiratory monitoring platforms for asthma and COPD adherence, overlapping directly with Aqsitania's AMASR-based chronic-respiratory telemonitoring offering and target user base.
• ResApp Health (acquired by Pfizer): ResApp developed smartphone-based respiratory-diagnostic algorithms (e.g., cough/sound analysis) for conditions such as COPD, asthma, and pneumonia — directly comparable to Aqsitania's software-based, non-effort-dependent respiratory assessment approach.

Broad incumbents

• ResMed: ResMed is a global leader in connected sleep and respiratory care devices (CPAP, ventilation) and now owns Propeller Health; it competes in the same chronic-respiratory monitoring category as Aqsitania but operates at vastly greater scale and with established payer/provider integration.
• Philips Respiratory Care: Philips is a major incumbent in hospital and home respiratory monitoring, ventilation, and telehealth; it competes broadly with Aqsitania across both hospital diagnostics (spirometry/ventilometry) and home telemonitoring, though not as a focused deep-tech niche player.

Emerging players

• Bodyport: Bodyport builds a connected cardiovascular-monitoring scale that captures cardiac and respiratory signals for heart-failure and chronic-disease management, partially overlapping with Aqsitania's cardiac and cardio-respiratory signal-analysis service line.
• VitalConnect: VitalConnect provides wearable biosensor patches and remote patient monitoring for cardiac and respiratory vital signs, an emerging-player analog to Aqsitania's connected-device-plus-software respiratory telemonitoring stack.
• Spire Health: Spire Health offers wearable continuous respiratory and sleep monitoring for chronic-condition management, overlapping with Aqsitania's home-based telemonitoring and chronic-respiratory signal-analysis capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aqsitania

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aqsitania